Pan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy
Authors:
- Paul R. BurchardPBPaul R. Burchard
- Luis I. RuffoloLRLuis I. Ruffolo
- Nicholas A. UllmanNUNicholas A. Ullman
- Benjamin S. DaleBDBenjamin S. Dale
- Yatee A. DaveYDYatee A. Dave
- Bailey K. HiltyBHBailey K. Hilty
- Jian YeJYJian Ye
- Mary GeorgerMGMary Georger
- Rachel JewellRJRachel Jewell
- Christine MillerCMChristine Miller
- Luis De Las CasasLCLuis De Las Casas
- Wolfgang JarolimekWJWolfgang Jarolimek
Open Access
- 1 August 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (8)
Abstract
Background: Cholangiocarcinoma (CCA) features highly desmoplastic stroma that promotes structural and functional resistance to therapy. Lysyl oxidases (LOX, LOXL1–4) catalyze collagen cross-linking, thereby increasing stromal rigidity and facilitating therapeutic resistance. Here, we evaluate the role of lysyl oxidases in stromal desmoplasia and the effects of pan-lysyl oxidase (pan-LOX) inhibition in CCA. Methods: Resected CCA and normal liver specimens were analyzed from archival tissues. Spontaneous and orthotopic murine models of intrahepatic CCA (iCCA) were used to assess the impact of the pan-LOX inhibitor PXS-5505 in treatment and correlative studies. The functional role of pan-LOX inhibition was interrogated through in vivo and ex vivo assays. Results: All 5 lysyl oxidases are upregulated in CCA and reduced lysyl oxidase expression is correlated with an improved prognosis in resected patients with CCA. Spontaneous and orthotopic murine models of intrahepatic cholangiocarcinoma upregulate all 5 lysyl oxidase isoforms. Pan-LOX inhibition reversed mechanical compression of tumor vasculature, resulting in improved chemotherapeutic penetrance and cytotoxic efficacy. The combination of chemotherapy with pan-LOX inhibition increased damage-associated molecular pattern release, which was associated with improved antitumor T-cell responses. Pan-LOX inhibition downregulated macrophage invasive signatures in vitro, rendering tumor-associated macrophages more susceptible to chemotherapy. Mice bearing orthotopic and spontaneously occurring intrahepatic cholangiocarcinoma tumors exhibited delayed tumor growth and improved survival following a combination of pan-LOX inhibition with chemotherapy. Conclusions: CCA upregulates all 5 lysyl oxidase isoforms, and pan-LOX inhibition reverses tumor-induced mechanical forces associated with chemotherapy resistance to improve chemotherapeutic efficacy and reprogram antitumor immune responses. Thus, combination therapy with pan-LOX inhibition represents an innovative therapeutic strategy in CCA. ExportKeywords
This publication has 50 references indexed in Scilit:
- An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategiesClinical and Translational Medicine, 2021
- Lysyl Oxidase‐Like 4 Fosters an Immunosuppressive Microenvironment During HepatocarcinogenesisHepatology, 2020
- Comprehensive analysis on the expression levels and prognostic values of LOX family genes in kidney renal clear cell carcinomaCancer Medicine, 2020
- Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver FibrosisHepatology, 2020
- Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic CholangiocarcinomaHepatology, 2019
- Lysyl oxidases: linking structures and immunity in the tumor microenvironmentCancer Immunology, Immunotherapy, 2019
- Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null GliomaCancer Cell, 2019
- Treatment and Prognosis for Patients With Intrahepatic CholangiocarcinomaJAMA Surgery, 2014
- Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targetingHepatology, 2013
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal AdenocarcinomaCancer Cell, 2012